GH2616 / Genhouse Bio - LARVOL DELTA

A Dose-Escalation, Dose-Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GH2616 Tablets in Subjects With Advanced Solid Tumors(StudyID:GH2616-101) (ChiCTR) - P1 | N=156 | Recruiting | Sponsor: Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

New P1 trial • Breast Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • EGFR • ROS1 • TP53

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Suzhou Genhouse Bio Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=156 | Not yet recruiting | Sponsor: Suzhou Genhouse Bio Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Discovery of GH2616, a potent and selective KIF18A inhibitor with robust in vivo efficacy in p53 mutant cancer (AACR 2023) - "In conclusion, we discovered GH2616 as a novel KIF18A inhibitor with potent in vivo efficacy. It is currently under evaluation in IND-enabling studies and IND filing is expected in Q4, 2023."

Preclinical • Oncology • KIF18A